initial public offerings (IPOs) trading on American exchanges

Friday, September 15, 2017

Neos Therapeutics (NEOS)

  • Headquarters: Grand Prairie, TX
  • Founded: 1994
  • IPO July 23, 2015; priced its IPO of 4.8M shares (up from 4M) of common stock at $15 per share.
The pharmaceutical firm develops products based on its proprietary modified-release drug delivery platform for the treatment of attention deficit hyperactivity disorder (ADHD). It currently markets only one product: a generic hydrocodone (narcotic cough suppressant) polistirex and chlorpheniramine (antihistamine) polistirex extended-release liquid suspension branded as Tussionex for the relief of cough and upper respiratory symptoms associated with allergy or cold in patients at least six years old.

Its three leading pipeline product candidates are: NT-0102, NT-0202 and NT-0201, all for the treatment of ADHD.


Neos Therapeutics receives U.S. FDA Approval of Adzenys ER (amphetamine) extended-release oral suspension for the treatment of ADHD in patients 6 years and older; to launch third medication in ADHD franchise in January 2018



Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.

Key stats and ratios

Q2 (Jun '17)2016
Net profit margin-380.40%-910.35%
Operating margin-333.69%-847.64%
EBITD margin--799.06%
Return on average assets-68.92%-82.24%
Return on average equity-394.99%-216.94%

No comments:

Post a Comment